[BIC-announce] FW: Killam Lecture February 3rd, 2009 Toward Understanding Polyglutamine Neurodegeneration

[Jennifer Chew, Ms.]

PLEASE DISCARD IF THIS IS A SUPLICATE.  THANK YOU.  jENNIFER
 
 

Jennifer Chew

McConnell Brain Imaging Centre

MNI - WB317

3801 University Street

Montreal, Qc  H3A 2B4

Telephone:  514-398-8554

Fax:  514-398-2975

 

 

________________________________

From: MNISTAFF - Montreal Neurological Institute Staff
[mailto:MNISTAFF at LISTS.MCGILL.CA] On Behalf Of Enza Ferracane, Ms.
Sent: Monday, February 02, 2009 10:12 AM
To: MNISTAFF at LISTS.MCGILL.CA
Subject: Killam Lecture February 3rd, 2009



Killam Lecture

 

Speaker:  Henry Paulson, MD, PhD

Department of Neurology

University of Michigan, Ann Arbor, MI

 

Title:  Toward Understanding Polyglutamine Neurodegeneration

 

Date:  February 3, 2009

 

Time:  4:00 pm

 

Place:  de Grandpre Communications Centre

 

 

________________________________

 

Dear Colleagues,

The Killam speaker this week will be Dr Henry L. Paulson, M.D., Ph.D.,
the Lucile Groff Professor of Neurology in the Department of Neurology
at the University of Michigan. Hank oversees departmental programs in
neurodegenerative diseases. He received his M.D. and Ph.D. in Cell
Biology from Yale University in 1990, then completed neurology residency
and neurogenetics and movement disorders fellowships at the University
of Pennsylvania. His research and clinical interests concern the causes
and treatment of age-related neurodegenerative diseases, with particular
interest in hereditary ataxias, polyglutamine disorders and Alzheimer's
disease. His lab described abnormal protein aggregates in polyglutamine
diseases, which now are recognized as a pathological hallmark in this
important class of inherited diseases. Using in vitro, cell-based and
various animal models, he and his labmates have contributed to advances
in the understanding of polyglutamine and other neurodegenerative
diseases. A current area of focus is defining the links between the
various protein quality control components that "handle" abnormal
proteins in neurodegenerative diseases, including molecular chaperones,
ubiquitin ligases and de-ubiquitnating enzymes. His lab also has helped
pioneer the use of RNA interference as potential therapy for hereditary
neurological disorders caused by "toxic" mutant genes. Hank serves on
the scientific advisory boards of numerous disease-related
organizations, and belongs to the Board of Scientific Counselors at the
National Institute for Neurological Disorders and Stroke at the National
Institutes of Health. Among his awards, Dr. Paulson has been an Ellison
Medical Foundation New Scholar in Aging and a recipient of the Paul
Beeson Physician Faculty Scholar in Aging Award from the American
Federation for Aging Research. His recent papers include:

Todi SV, et al. Ubiquitination directly enhances activity of the
deubiquitinating enzyme ataxin-3. EMBO J. 2009 Jan 15. [Epub ahead of
print]
 
Williams AJ, et al. In vivo suppression of polyglutamine neurotoxicity
by C-terminus of Hsp70-interacting protein (CHIP) supports an
aggregation model of pathogenesis. Neurobiol Dis. 2008 Nov 8. [Epub
ahead of print]
 
Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein
misfolding revisited. Trends Neurosci. 2008 Oct;31(10):521-8.
 
Winborn BJ, et al. The deubiquitinating enzyme ataxin-3, a polyglutamine
disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains.
J Biol Chem. 2008 Sep 26;283(39):26436-43.
 
Glenn KA, et al.Diversity in tissue expression, substrate binding, and
SCF complex formation for  a lectin family of ubiquitin ligases. J Biol
Chem. 2008 May 9;283(19):12717-29. 
 
Nelson RF, et al. Selective cochlear degeneration in mice lacking the
F-box protein, Fbx2, a glycoprotein-specific ubiquitin ligase subunit. J
Neurosci. 2007 May 9;27(19):5163-71.
 
Gonzalez-Alegre P, Paulson HL. Technology insight: therapeutic RNA
interference--how far from the neurology clinic? Nat Clin Pract Neurol.
2007 Jul;3(7):394-404.

Hank is a very engaging speaker. Please join us for what promises to be
a very interesting seminar.
 
Ted

-------------------------
Edward A. Fon, MD, FRCP(C)
Director, McGill Parkinson Program
and NPF Center of Excellence
Montreal Neurological Institute
Associate Professor
McGill University
Office: (514) 398-8398
Lab: (514) 398-5057
Fax: (514) 398-5214
ted.fon at mcgill.ca
http://www.mni.mcgill.ca/neuro_team/neuronal_survival/edward_fon/